Last reviewed · How we verify
NCT04587700
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery
trial in Cannabis in 5 participants. Completed in 5 July 2023.
5 July 2023
Quick facts
| Lead sponsor | University of Alberta |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5 |
| Start date | 21 September 2020 |
| Primary completion | 5 July 2023 |
| Estimated completion | 5 July 2023 |
| Sites | 1 location across Canada |
Conditions studied
Sponsor
University of Alberta
Who can join
Adults 18 to 75, any sex, with Cannabis or Marijuana. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Marijuana use has increased since its legalization in Canada and many believe that it may help patients that are experiencing chronic pain. The investigators want to assess if patients who have used marijuana chronically will need more medication to control their pain after they have undergone orthopedic trauma surgery (ex. Hip, femur, humerus fractures etc.). In this study, the investigators will identify chronic marijuana users (ie. those using for 3 months or more) who are undergoing orthopedic trauma surgery to assess how much pain medication they need post-operatively and compare this with non-users. The investigators will also evaluate their pain scores, pain medication use and other complications that they may have during or after their surgeries, including any nausea/vomiting, heart or breathing problems.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04587700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cannabis
Currently open trials in the same condition.
- NCT05999383 — Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration · Phase 2 · recruiting
- NCT07417059 — Sex Hormones Impact on Cannabis Response · NA · recruiting
- NCT07194018 — Use of Cannabis Oil in Fibromyalgia · active not recruiting
- NCT06099379 — Modulation of THC Effects by CBD: a Dose-ranging Study · Phase 1, PHASE2 · recruiting
- NCT05742724 — The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol · Phase 1 · active not recruiting
Other University of Alberta trials
Trials by the same sponsor.
- NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
- NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
- NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04587700 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alberta
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04587700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing